NSE: LUPIN | BSE: 500257

Mid-range Performer

Download real time

2034.40 42.55 (2.14%)

36.24% Gain from 52W Low

510.9K NSE+BSE Volume

NSE 18 Mar, 2025 3:16 PM (IST)

92,878.7

Market Cap

High in industry

0.6

Beta 1Year

Very Low volatility

US FDA Approval

Lupin gets US FDA tentative approval for Amifampridine tablets, with a market size of $306 million See details

Lupin Ltd. Corporate Filings & Announcements

Latest corporate announcements and filings from Lupin Ltd. on BSE

Load latest

30 Jan 2025

2034.40

2.14%

Company Update

LUPIN LTD. - 500257 - Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS

BSE India

Intimation regarding allotment of 246462 shares under ESOP.

27 Jan 2025

2034.40

2.14%

Company Update

LUPIN LTD. - 500257 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

BSE India

Earnings Call for Q3 FY25 is scheduled on Wednesday, February 12, 2025, at 18:30 hrs (IST).

27 Jan 2025

2034.40

2.14%

Board Meeting

LUPIN LTD. - 500257 - Board Meeting Intimation for Considering And Approving The Unaudited Standalone And …

BSE India

LUPIN LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/02/2025 ,inter alia, to consider and approve Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and nine-months ended December 31, 2024 and other business matters.

20 Jan 2025

2034.40

2.14%

Company Update

LUPIN LTD. - 500257 - Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS

BSE India

Intimation regarding grant of 233,945 Stock Options

09 Jan 2025

2034.40

2.14%

Company Update

LUPIN LTD. - 500257 - Announcement under Regulation 30 (LODR)-Updates on Acquisition

BSE India

The Company has completed the acquisition of 42.61% of the equity share capital of Sunsure Solarpark Seventeen Private Limited, in the capacity as a Captive User.

08 Jan 2025

2034.40

2.14%

Company Update

LUPIN LTD. - 500257 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

BSE India

Lupin Receives EIR from U. S. FDA for its Pithampur Unit-1 Facility with VAI Classification.

06 Jan 2025

2034.40

2.14%

Company Update

LUPIN LTD. - 500257 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

BSE India

Certificate under Reg 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended December 31, 2018.

02 Jan 2025

2034.40

2.14%

Company Update

LUPIN LTD. - 500257 - Intimation Regarding Change In Name Of Registrar And Share Transfer Agent …

BSE India

Intimation regarding change in name of Registrar and Share Transfer Agent of the Company.

30 Dec 2024

2034.40

2.14%

Company Update

LUPIN LTD. - 500257 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

BSE India

Lupin Acquires Huminsulin from Eli Lilly and Company to further enhance Diabetes portfolio.

27 Dec 2024

2034.40

2.14%

SAST

LUPIN LTD. - 500257 - Closure of Trading Window

BSE India

Intimation regarding closure of trading window.

Is Lupin Ltd. worth buying?

907 Votes:

Buy 72.66%

Sell 17.64%

Hold 9.7%

RESEARCH REPORTS

Hold SEE REPORTS >

Buy SEE REPORTS >